 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | Journal: Intravitreal steroid implants in the management of noninfectious intermediate and posterior uveitis. (Pubmed Central) - Sep 22, 2024
Dexamethasone implants favor the therapeutic goal of prevention of recurrences, whereas the use of fluocinolone implants helps to attain better visual outcomes due to their longer duration of action. Thus, the review provides recent literature supporting the role and indication of sustained release intravitreal implants in the management of noninfectious intermediate and posterior uveitis.
- | Yutiq (fluocinolone acetonide intravitreal implant) / EyePoint Pharma
Journal: Injectable Fluocinolone Implant for the Management of Cystoid Macular Edema in Coats' Disease. (Pubmed Central) - Aug 12, 2024
The authors conclude that a long-acting steroid implant may be beneficial in select patients with Coats' disease. [Ophthalmic Surg Lasers Imaging Retina 2024;55:XX-XX.].
- || Yutiq (fluocinolone acetonide intravitreal implant) / EyePoint Pharma, Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
Review, Journal: Fluocinolone acetonide 0.2 (Pubmed Central) - May 30, 2024
As more clinical experience has been gained using FAc implants, it was necessary to update the clinical recommendations that guide patient management in the clinic. The current consensus document addresses relevant issues related to the use of FAc implants on different types of patients with various etiologies of NIU-PS, and was conducted to standardize approaches to help specialists obtain better clinical outcomes.
- | Ozurdex (dexamethasone intravitreal implant) / AbbVie, Yutiq (fluocinolone acetonide intravitreal implant) / EyePoint Pharma
Journal: Successful Treatment of Clinically Diagnosed Cancer-Associated Retinopathy with Intravitreal Dexamethasone Implant Followed by 0.18 mg Fluocinolone Implant without Systemic Immunosuppression. (Pubmed Central) - Feb 22, 2024
Long term follow-up is warranted. Further research is needed to evaluate the efficacy of using 0.18mg fluocinolone implant (YUTIQ) to treat CAR.
- || Yutiq (fluocinolone acetonide intravitreal implant) / EyePoint Pharma
Clinical data, Journal: Long-Term Clinical Outcomes of the 0.18 Mg Fluocinolone Acetonide Intravitreal Implant Following Local Corticosteroid Burst in Noninfectious Uveitis. (Pubmed Central) - Jan 9, 2024
No patient discontinued systemic therapy and on average 15.0% of eyes required additional local corticosteroids at each follow-up interval. This treatment approach demonstrates that the 0.18?mg FAi is a useful adjuvant for the treatment of noninfectious uveitis but may not be adequate as solo therapy.
- Ozurdex (dexamethasone intravitreal implant) / AbbVie, Xipere (triamcinolone acetonide) / Clearside Biomedical, Bausch Health, Arctic Vision, Yutiq (fluocinolone acetonide intravitreal implant) / EyePoint Pharma
Improvement of Postoperative Macular Edema Following Intravitreal Steroid Injections (POSTER THEATER) - Oct 28, 2023 - Abstract #AAO2023AAO_1661;
CST and MV improved significantly at 6 weeks (?129 ?m, P ? 10-13; ?0.88 mm
- ||| Yutiq (fluocinolone acetonide intravitreal implant) / EyePoint Pharma
Trial termination, Trial primary completion date: Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert (FAI) (clinicaltrials.gov) - Sep 8, 2023
P3, N=12, Terminated, Sponsor: EyePoint Pharmaceuticals, Inc.
10-13; ?0.88 mm Active, not recruiting --> Terminated | Trial primary completion date: Apr 2023 --> Oct 2022; No longer pursuing indication
- ||||| Yutiq (fluocinolone acetonide intravitreal implant) / EyePoint Pharma
Enrollment closed, Enrollment change, Trial primary completion date: Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert (FAI) (clinicaltrials.gov) - Dec 21, 2022
P3, N=12, Active, not recruiting, Sponsor: EyePoint Pharmaceuticals, Inc.
Active, not recruiting --> Terminated | Trial primary completion date: Apr 2023 --> Oct 2022; No longer pursuing indication Recruiting --> Active, not recruiting | N=60 --> 12 | Trial primary completion date: Oct 2022 --> Apr 2023
- | Yutiq (fluocinolone acetonide intravitreal implant) / EyePoint Pharma
Enrollment open: TYNI: The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment (clinicaltrials.gov) - Oct 31, 2022
P3, N=30, Recruiting, Sponsor: Texas Retina Associates
Recruiting --> Active, not recruiting | N=60 --> 12 | Trial primary completion date: Oct 2022 --> Apr 2023 Not yet recruiting --> Recruiting
- | Yutiq (fluocinolone acetonide intravitreal implant) / EyePoint Pharma
New trial: A Study of YUTIQ (clinicaltrials.gov) - Oct 25, 2022
P=N/A, N=15, Recruiting, Sponsor: Tianjin Medical University
- | Yutiq (fluocinolone acetonide intravitreal implant) / EyePoint Pharma
New P3 trial: TYNI: The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment (clinicaltrials.gov) - Aug 3, 2022
P3, N=30, Not yet recruiting, Sponsor: Texas Retina Associates
- | Yutiq (fluocinolone acetonide intravitreal implant) / EyePoint Pharma
Journal, Monotherapy: Efficacy of the Fluocinolone Acetonide (Yutiq) Intravitreal Implant as Monotherapy for Uveitis. (Pubmed Central) - Jul 7, 2022
The fluocinolone acetonide implant may not suffice as monotherapy for all patients with uveitis, but it may be effective as an adjunctive treatment. We propose a clinical workflow for the selection and treatment of patients who may benefit from it.
- ||| Yutiq (fluocinolone acetonide intravitreal implant) / EyePoint Pharma
Enrollment open: Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis (clinicaltrials.gov) - Jun 2, 2022
P4, N=125, Recruiting, Sponsor: EyePoint Pharmaceuticals, Inc.
We propose a clinical workflow for the selection and treatment of patients who may benefit from it. Not yet recruiting --> Recruiting
- |||| Yutiq (fluocinolone acetonide intravitreal implant) / EyePoint Pharma
New P4 trial: Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis (clinicaltrials.gov) - Apr 10, 2022
P4, N=125, Not yet recruiting, Sponsor: EyePoint Pharmaceuticals, Inc.
- |||| Yutiq (fluocinolone acetonide intravitreal implant) / EyePoint Pharma
Enrollment open: Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert (FAI) (clinicaltrials.gov) - Dec 3, 2021
P3, N=60, Recruiting, Sponsor: EyePoint Pharmaceuticals, Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||| Yutiq (fluocinolone acetonide intravitreal implant) / EyePoint Pharma
New P3 trial: Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert (FAI) (clinicaltrials.gov) - Oct 6, 2021
P3, N=60, Not yet recruiting, Sponsor: EyePoint Pharmaceuticals, Inc.
- | Yutiq (fluocinolone acetonide intravitreal implant) / EyePoint Pharma
Journal: Yutiq - another fluocinolone intravitreal implant for uveitis. (Pubmed Central) - Sep 30, 2021
Not yet recruiting --> Recruiting No abstract available
- | Yutiq (fluocinolone acetonide intravitreal implant) / EyePoint Pharma
Enrollment open, Surgery: A Study of Yutiq Steroid Insert During Glaucoma Tube Implant Surgery (clinicaltrials.gov) - Aug 26, 2021
P1, N=5, Recruiting, Sponsor: Sanjay Asrani
No abstract available Not yet recruiting --> Recruiting
- | Yutiq (fluocinolone acetonide intravitreal implant) / EyePoint Pharma
New P1 trial, Surgery: A Study of Yutiq Steroid Insert During Glaucoma Tube Implant Surgery (clinicaltrials.gov) - Jun 8, 2021
P1, N=5, Not yet recruiting, Sponsor: Sanjay Asrani
- Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Analysis of Urgent Follow Up Visits and Complications After Intravitreal Injections: A Retrospective Cohort Study () - May 13, 2021 - Abstract #ARVO2021ARVO_2625;
Intravitreal injections resulted in an incidence of 0.60% urgent unscheduled follow-up visits within 7 days of injection in this large retinal specialty practice. Blurred vision and symptoms of PVD were the most common causes of urgent visits.
- | Yutiq (fluocinolone acetonide intravitreal implant) / EyePoint Pharma
Journal: Preliminary evaluation of YUTIQ™ (fluocinolone acetonide intravitreal implant 0.18 mg) in posterior uveitis. (Pubmed Central) - Jun 9, 2020
The treatment goal is to target the site of inflammation with low dose of corticosteroids, delivered over an extended period of time, to minimize the cumulative damage resulting from repeated recurrences, reducing both injections frequency and ocular side effects. This article will review the pharmacology and preliminary clinical data of the 0.18 mg fluocinolone acetonide intravitreal implant (YUTIQ™), to show its efficacy and safety in the treatment of noninfectious posterior uveitis.